New stock news | Yingpai Pharmaceuticals plans to list in Hong Kong. The China Securities Regulatory Commission requires additional clarification on matters such as past capital increases and pricing basis for equity transfers.

It was learned from the Zhitong Finance and Economics APP that on November 14th, the China Securities Regulatory Commission announced the "Supplementary Materials Requirements for Overseas Issuance and Listing Record Filing (November 10, 2025 - November 14, 2025)". The International Department of the China Securities Regulatory Commission released the supplementary material requirements for 10 enterprises, among which it was mentioned that Yingpai Pharmaceutical Industry is required to provide explanations for the pricing basis of previous capital increases and equity transfer, as well as whether there are any shareholding arrangements since its establishment. According to the disclosure by the Hong Kong Stock Exchange on September 26th, Nanjing Yingpai Pharmaceutical Industry Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs and China International Capital Corporation as joint sponsors.